Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Oct 15, 2025; 17(10): 110203
Published online Oct 15, 2025. doi: 10.4251/wjgo.v17.i10.110203
Published online Oct 15, 2025. doi: 10.4251/wjgo.v17.i10.110203
Rectal neuroendocrine tumors in a Latin American population: Insights from a Peruvian national cancer institute
Wagner Eduardo Cruz-Diaz, Angela Leonardo, Alexandra Saavedra, Victor Paitan, Juan Haro-Varas, Jackeline Macetas, Eder Veramendi, Cristian Pacheco, Mónica Calderón, Tatiana Vidaurre, Victor Castro-Oliden, Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Peru
Raul Mantilla, Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru
Author contributions: Cruz-Díaz WE participated in the study conception and design, developed the methodology, and prepared the original draft of the manuscript; Leonardo A and Saavedra A contributed to the data collection and curation; Paitan V and Haro-Varas J supervised the initial manuscript drafting; Paitan V, Haro-Varas J Macetas J, Veramendi E, and Pacheco C contributed to the review and editing of the manuscript; Mantilla R conducted statistical analysis; Calderon M, Vidaurre T, and Castro-Oliden V provided expert guidance, supervision, and critical review of the final version for important intellectual content. All authors critically reviewed and provided final approval of the manuscript and were responsible for the decision to submit the manuscript for publication.
Institutional review board statement: This retrospective study was approved by the Ethics Committee of Instituto Nacional de Enfermedades Neoplásicas (Approval No. INEN 25-18).
Informed consent statement: The need for patient consent was waived due to the retrospective nature of the study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wagner Eduardo Cruz-Diaz, MD, Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Avenida Angamos Este 2520, Surquillo, Lima 15038, Peru. wagner.cruz@upch.pe
Received: June 4, 2025
Revised: July 17, 2025
Accepted: September 8, 2025
Published online: October 15, 2025
Processing time: 136 Days and 6.2 Hours
Revised: July 17, 2025
Accepted: September 8, 2025
Published online: October 15, 2025
Processing time: 136 Days and 6.2 Hours
Core Tip
Core Tip: This retrospective study encompassed the largest known Peruvian patients with well-differentiated rectal neuroendocrine tumors. With a median overall survival of 76 months and a 5-year survival rate of 60.6%, outcomes were significantly affected by tumor size, grade, and nodal status. Grade 2 tumors, lesions > 20 mm, and nodal involvement were linked to poorer survival. These findings provide important regional data and support the integration of these factors into risk-stratification strategies for rectal neuroendocrine tumors in Perú.